BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:A tumoral stromal cell that mediates immune suppression - Douglas 
 T. Fearon\, Wellcome Trust Immunology Unit\, Cambridge
DTSTART:20100106T130000Z
DTEND:20100106T140000Z
UID:TALK21927@talks.cam.ac.uk
CONTACT:Katrien Van Look
DESCRIPTION:The finding by Boon of the Cancer-Testis Antigen family of tum
 or-associated antigens in 1991 enabled\ntherapeutic cancer vaccination to 
 be rigorously tested. Despite vaccination with peptides\, recombinant\npro
 teins\, and viral vectors expressing CT antigens\, which induced antigen-s
 pecific T cells\, control of tumor\ngrowth has not been achieved. Studies 
 in humans and in mice suggest that this outcome is caused by\nimmune suppr
 ession within the tumor microenvironment. Stromal cells of the innate and 
 adaptive\nimmune systems have been thought to mediate this suppression\, a
 nd less attention has been given to\nmesenchymal stromal cells. We have ge
 nerated mice that permit the conditional ablation of a stromal cell\ntype 
 of presumed mesenchymal origin that is found in all human adenocarcinomas 
 and other examples\nof “healing wounds”. The loss of this stromal cell
  type\, which comprises only ~2% of all tumoral cells\,\nleads to regressi
 on of an established immunogenic tumor. Control of the development or func
 tion of\nthis stromal cell in human tumors may improve the efficacy of the
 rapeutic cancer vaccines.
LOCATION:Cancer Research UK Cambridge Research Institute\, Lecture Theatre
END:VEVENT
END:VCALENDAR